Protagonist Therapeutics, Inc. (NASDAQ:PTGX) | WebDisclosure

Basculer en Français

8646	Companies
145877	Keywords
81587	Articles
78094	Press releases

Headlines Articles Press releases Protagonist Therapeutics, Inc.

Home
Companies
Protagonist Therapeutics, Inc.

PRESS RELEASE

published on 02/21/2025 at 13:00, 2 months 13 days ago

Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Protagonist Therapeutics reports $165.0 million milestone achieved in Q4 2024 and key milestones for 2025 including icotrokinra and rusfertide trial results. Financial results for Q4 2024 revealed

Financial Results Clinical Trial Milestone Protagonist Therapeutics Rusfertide
BRIEF

published on 01/30/2025 at 00:20, 3 months 7 days ago

Protagonist Therapeutics annonce un événement destiné aux investisseurs axé sur la polycythémie vraie et le rusfertide

Essais Cliniques Rusfertide Thérapeutique Protagoniste Événement Pour Les Investisseurs Polycythémie Vraie
BRIEF

published on 01/30/2025 at 00:20, 3 months 7 days ago

Protagonist Therapeutics Announces Investor Event Focused on Polycythemia Vera and Rusfertide

Clinical Trials Investor Event Protagonist Therapeutics Rusfertide Polycythemia Vera
PRESS RELEASE

published on 01/30/2025 at 00:15, 3 months 7 days ago

Protagonist to Host Investor Event with KOL Insights on Polycythemia Vera (PV) and the Hepcidin Mimetic Rusfertide in New York on February 6, 2025
Protagonist Therapeutics to host investor event discussing Rusfertide Phase 3 VERIFY study design and Phase 2 data with key opinion leaders. Company also to provide commercial opportunity snapshot. Live Q&A session and lunch included

Investor Event Protagonist Therapeutics Rusfertide Phase 3 VERIFY Study Commercial Opportunity
BRIEF

published on 01/06/2025 at 22:10, 3 months 30 days ago

Protagonist Therapeutics annonce des primes d'encouragement à un nouveau dirigeant

Nasdaq Thérapeutique Protagoniste Options Sur Actions Primes D'encouragement Nouveau Comité Exécutif
BRIEF

published on 01/06/2025 at 22:10, 3 months 30 days ago

Protagonist Therapeutics Announces Inducement Awards to New Executive

Stock Options Nasdaq Protagonist Therapeutics Inducement Awards New Executive
PRESS RELEASE

published on 01/06/2025 at 22:05, 3 months 30 days ago

Protagonist Therapeutics Reports Granting of Inducement Awards
Protagonist Therapeutics grants inducement awards to Dr. Newman Yeilding for the role of Executive Vice President, Chief Scientific Officer, under inducement plan. Company's focus on peptide therapeutics and Phase 3 drug development

Protagonist Therapeutics Phase 3 Clinical Development Inducement Awards Peptide Therapeutics Drug Candidates
BRIEF

published on 12/19/2024 at 22:10, 4 months 17 days ago

Protagonist Therapeutics to Present at J.P. Morgan Healthcare Conference

Protagonist Therapeutics Rusfertide Icotrokinra Biopharmaceutical Development J.P. Morgan Conference
BRIEF

published on 12/19/2024 at 22:10, 4 months 17 days ago

Protagonist Therapeutics présentera ses produits à la conférence JP Morgan Healthcare

Rusfertide Thérapeutique Protagoniste Icotrokinra Développement Biopharmaceutique Conférence De JP Morgan
PRESS RELEASE

published on 12/19/2024 at 22:05, 4 months 17 days ago

Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025
Protagonist Therapeutics to present company overview at 43rd Annual J.P. Morgan Healthcare Conference. Highlights late-stage peptides in clinical development

Clinical Development Biopharmaceutical Protagonist Therapeutics J.P. Morgan Healthcare Conference Peptides

Accesswire

Published on 05/06/2025 at 15:35, 53 minutes ago

ACCESS Newswire to Host First Quarter Earnings Conference Call on May 13, 2025
Published on 05/06/2025 at 15:15, 1 hour 13 minutes ago

urban-gro, Inc. Awarded New Construction Contract with Fogo de Chão
Published on 05/06/2025 at 15:15, 1 hour 13 minutes ago

RLTR's "RI" Unshackled from Tariffs and Chip Wars, Widening Its Lead Over Traditional AI
Published on 05/06/2025 at 14:31, 1 hour 57 minutes ago

Monogram Technologies to Host First Quarter 2025 Results Conference Call on Wednesday, May 14, 2025 at 4:30 p.m. Eastern Time
Published on 05/06/2025 at 14:30, 1 hour 58 minutes ago

Gladstone Commercial Corporation Earnings Call and Webcast Information

View all ACCESSWIRE

EQS Group

Published on 05/06/2025 at 15:25, 1 hour 2 minutes ago

Amundi Physical Metals plc: UK Final Terms
Published on 05/06/2025 at 15:18, 1 hour 9 minutes ago

Amundi Physical Metals plc: Final Terms
Published on 05/06/2025 at 15:15, 1 hour 13 minutes ago

Accelleron Annual General Meeting approves all board proposals
Published on 05/06/2025 at 15:00, 1 hour 28 minutes ago

Eleving Group: Unaudited 3M 2025 results on 12 May 2025 - Invitation to the Earnings Call on 13 May 2025
Published on 05/06/2025 at 15:00, 1 hour 28 minutes ago

The European Association of Endoscopic Spine Surgery is born to lead medical excellence and surgical innovation in Europe

Les Echos

Published on 05/06/2025 at 10:31, 5 hours 56 minutes ago

Déclaration du nombre d’actions et droits de vote au 30 avril 2025
Published on 05/06/2025 at 10:31, 5 hours 56 minutes ago

Disclosure of Share Capital and Voting Rights as of April 30, 2025
Published on 05/06/2025 at 08:51, 7 hours 37 minutes ago

ENGIE - déclaration mensuelle du nombre total d'actions et de droits de vote composant le capital au 30 avril 2025
Published on 05/06/2025 at 08:30, 7 hours 58 minutes ago

Cie du Bois Sauvage: Terugkoop van eigen aandelen – Week van 28/04/2025 tot 02/05/2025
Published on 05/06/2025 at 08:30, 7 hours 58 minutes ago

Cie du Bois Sauvage : Rachat d’actions propres – semaine du 28/04/2025 au 02/05/2025

View all LES ECHOS COMFI WIRE